Cargando…

CCL2 Is Associated with a Faster Rate of Cognitive Decline during Early Stages of Alzheimer's Disease

Chemokine (C-C motif) receptor 2 (CCR2)-signaling can mediate accumulation of microglia at sites affected by neuroinflammation. CCR2 and its main ligand CCL2 (MCP-1) might also be involved in the altered metabolism of beta-amyloid (Aβ) underlying Alzheimer's disease (AD). We therefore measured...

Descripción completa

Detalles Bibliográficos
Autores principales:	Westin, Karin, Buchhave, Peder, Nielsen, Henrietta, Minthon, Lennart, Janciauskiene, Sabina, Hansson, Oskar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3268759/ https://www.ncbi.nlm.nih.gov/pubmed/22303443 http://dx.doi.org/10.1371/journal.pone.0030525

Ejemplares similares

Longitudinal Study of CSF Biomarkers in Patients with Alzheimer's Disease
por: Buchhave, Peder, et al.
Publicado: (2009)

Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease
por: Stomrud, Erik, et al.
Publicado: (2010)

The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer’s but Not Parkinson’s Disease or Dementia with Lewy Bodies
por: Wennström, Malin, et al.
Publicado: (2015)

No Diagnostic Value of Plasma Clusterin in Alzheimer's Disease
por: Silajdžić, Edina, et al.
Publicado: (2012)

A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease
por: Palmqvist, Sebastian, et al.
Publicado: (2010)

Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease
por: Björkqvist, Maria, et al.
Publicado: (2012)

NG2 cells, a new trail for Alzheimer’s disease mechanisms?
por: Nielsen, Henrietta M, et al.
Publicado: (2013)

Tau Pathology and Parietal White Matter Lesions Have Independent but Synergistic Effects on Early Development of Alzheimer's Disease
por: Hertze, Joakim, et al.
Publicado: (2013)

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study
por: Hertze, Joakim, et al.
Publicado: (2014)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Air pollution is associated with faster cognitive decline in Alzheimer's disease
por: Lee, Young‐gun, et al.
Publicado: (2023)

Low CSF Levels of Both α-Synuclein and the α-Synuclein Cleaving Enzyme Neurosin in Patients with Synucleinopathy
por: Wennström, Malin, et al.
Publicado: (2013)

Plasma tau levels in Alzheimer's disease
por: Zetterberg, Henrik, et al.
Publicado: (2013)

Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease
por: Kumar, Atul, et al.
Publicado: (2021)

Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer’s Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study
por: Palmqvist, Sebastian, et al.
Publicado: (2012)

Kynurenic Acid Levels in Cerebrospinal Fluid from Patients with Alzheimer’s Disease or Dementia with Lewy Bodies
por: Wennström, Malin, et al.
Publicado: (2014)

Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer’s disease
por: Schultz, Nina, et al.
Publicado: (2019)

Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer’s disease
por: Benedictus, Marije R., et al.
Publicado: (2016)

Misidentification Subtype of Alzheimer's Disease Psychosis Predicts a Faster Cognitive Decline
por: D'Antonio, Fabrizia, et al.
Publicado: (2019)

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease
por: Henjum, Kristi, et al.
Publicado: (2016)

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
por: Palmqvist, Sebastian, et al.
Publicado: (2015)

The effect of white matter hyperintensities on statistical analysis of diffusion tensor imaging in cognitively healthy elderly and prodromal Alzheimer's disease
por: Svärd, Daniel, et al.
Publicado: (2017)

Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients
por: Wennström, Malin, et al.
Publicado: (2015)

Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer’s disease
por: Patra, Kalicharan, et al.
Publicado: (2018)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Involvement of Matrix Metalloproteinase-9 in Amyloid-β 1–42–Induced Shedding of the Pericyte Proteoglycan NG2
por: Schultz, Nina, et al.
Publicado: (2014)

Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease
por: Malek-Ahmadi, Michael, et al.
Publicado: (2019)

Specific depression dimensions are associated with a faster rate of cognitive decline in older adults
por: Soleimani, Laili, et al.
Publicado: (2022)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
por: Mulugeta, Ezra, et al.
Publicado: (2011)

Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease
por: Voevodskaya, Olga, et al.
Publicado: (2016)

Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy
por: Wattmo, Carina, et al.
Publicado: (2016)

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease
por: Andersson, Carl-Henrik, et al.
Publicado: (2016)

Predictors of long-term cognitive outcome in Alzheimer's disease
por: Wattmo, Carina, et al.
Publicado: (2011)

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease
por: Pichet Binette, Alexa, et al.
Publicado: (2022)

Solitary living in Alzheimer’s disease over 3 years: association between cognitive and functional impairment and community-based services
por: Wattmo, Carina, et al.
Publicado: (2014)

Distinct cerebrospinal fluid amyloid β peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease
por: Portelius, Erik, et al.
Publicado: (2010)

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease
por: Brinkmalm, Ann, et al.
Publicado: (2014)

Faster Cognitive and Functional Decline in Dysexecutive versus Amnestic Alzheimer's Subgroups: A Longitudinal Analysis of the National Alzheimer's Coordinating Center (NACC) Database
por: Mez, Jesse, et al.
Publicado: (2013)

Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
por: Cullen, Nicholas C., et al.
Publicado: (2021)

Response to cholinesterase inhibitors affects lifespan in Alzheimer’s disease
por: Wattmo, Carina, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fpm65m93mub8m642kpqsq45aur